Literature DB >> 22304713

GCPII imaging and cancer.

C A Foss1, R C Mease, S Y Cho, H J Kim, M G Pomper.   

Abstract

Glutamate carboxypeptidase II (GCPII) in the central nervous system is referred to as the prostate-specific membrane antigen (PSMA) in the periphery. PSMA serves as a target for imaging and treatment of prostate cancer and because of its expression in solid tumor neovasculature has the potential to be used in this regard for other malignancies as well. An overview of GCPII/PSMA in cancer, as well as a discussion of imaging and therapy of prostate cancer using a wide variety of PSMA-targeting agents is provided.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22304713      PMCID： PMC4076792          DOI： 10.2174/092986712799462612

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN： 0929-8673            Impact factor:   4.530


  208 in total

Review 1.  Molecular-functional imaging of cancer: to image and imagine.

Authors:  Kristine Glunde; Arvind P Pathak; Zaver M Bhujwalla
Journal:  Trends Mol Med       Date:  2007-06-04       Impact factor: 11.951

2.  11C/ 18F-choline PET or 11C/18F-acetate PET in prostate cancer: may a choice be recommended?

Authors:  Cristina Nanni; Paolo Castellucci; Mohsen Farsad; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10       Impact factor: 9.236

Review 3.  Cell-specific aptamers for targeted therapies.

Authors:  Laura Cerchia; Paloma H Giangrande; James O McNamara; Vittorio de Franciscis
Journal:  Methods Mol Biol       Date:  2009

4.  Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis.

Authors:  Sebastian Mannweiler; Peter Amersdorfer; Slave Trajanoski; Jonathan A Terrett; David King; Gabor Mehes
Journal:  Pathol Oncol Res       Date:  2008-09-18       Impact factor: 3.201

5.  Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate.

Authors:  Takahito Nakajima; Makoto Mitsunaga; Neil H Bander; Warren D Heston; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2011-07-27       Impact factor: 4.774

6.  High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen.

Authors:  Valerie Humblet; Rena Lapidus; Larry R Williams; Takashi Tsukamoto; Camilo Rojas; Pavel Majer; Bunda Hin; Shunsuke Ohnishi; Alec M De Grand; Atif Zaheer; Jürgen T Renze; Akira Nakayama; Barbara S Slusher; John V Frangioni
Journal:  Mol Imaging       Date:  2005 Oct-Dec       Impact factor: 4.488

7.  Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3.

Authors:  Piotr Laidler; Joanna Dulińska; Małgorzata Lekka; Janusz Lekki
Journal:  Arch Biochem Biophys       Date:  2005-03-01       Impact factor: 4.013

Review 8.  Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development.

Authors:  Yarí E Marín; Suzie Chen
Journal:  J Mol Med (Berl)       Date:  2004-08-21       Impact factor: 4.599

9.  Activity-dependent NFATc3 nuclear accumulation in pericytes from cortical parenchymal microvessels.

Authors:  Jessica A Filosa; Mark T Nelson; Laura V Gonzalez Bosc
Journal:  Am J Physiol Cell Physiol       Date:  2007-09-19       Impact factor: 4.249

Review 10.  Receptor-mediated endocytosis: the intracellular journey of transferrin and its receptor.

Authors:  A Dautry-Varsat
Journal:  Biochimie       Date:  1986-03       Impact factor: 4.079
View more
  34 in total

1.  [(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA).

Authors:  Xing Yang; Ronnie C Mease; Mrudula Pullambhatla; Ala Lisok; Ying Chen; Catherine A Foss; Yuchuan Wang; Hassan Shallal; Hannah Edelman; Adam T Hoye; Giorgio Attardo; Sridhar Nimmagadda; Martin G Pomper
Journal:  J Med Chem       Date:  2015-12-16       Impact factor: 7.446

Review 2.  The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.

Authors:  Benjamin T Ristau; Denise S O'Keefe; Dean J Bacich
Journal:  Urol Oncol       Date:  2013-12-08       Impact factor: 3.498

3.  ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.

Authors:  Steven P Rowe; Kenneth L Gage; Sheila F Faraj; Katarzyna J Macura; Toby C Cornish; Nilda Gonzalez-Roibon; Gunes Guner; Enrico Munari; Alan W Partin; Christian P Pavlovich; Misop Han; H Ballentine Carter; Trinity J Bivalacqua; Amanda Blackford; Daniel Holt; Robert F Dannals; George J Netto; Martin A Lodge; Ronnie C Mease; Martin G Pomper; Steve Y Cho
Journal:  J Nucl Med       Date:  2015-06-11       Impact factor: 10.057

4.  Maternal inflammation leads to impaired glutamate homeostasis and up-regulation of glutamate carboxypeptidase II in activated microglia in the fetal/newborn rabbit brain.

Authors:  Zhi Zhang; Bassam Bassam; Ajit G Thomas; Monica Williams; Jinhuan Liu; Elizabeth Nance; Camilo Rojas; Barbara S Slusher; Sujatha Kannan
Journal:  Neurobiol Dis       Date:  2016-06-17       Impact factor: 5.996

5.  Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer.

Authors:  Joseph R Osborne; Teja M Kalidindi; Blesida J Punzalan; Kishore Gangangari; Daniel E Spratt; Wolfgang A Weber; Steven M Larson; Naga Vara Kishore Pillarsetty
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

6.  68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.

Authors:  Francesco Ceci; Paolo Castellucci; Tiziano Graziani; Andrea Farolfi; Cristina Fonti; Filippo Lodi; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-22       Impact factor: 9.236

7.  Characterization of a novel metastatic prostate cancer cell line of LNCaP origin.

Authors:  Mark A Castanares; Ben T Copeland; Wasim H Chowdhury; Minzhi M Liu; Ronald Rodriguez; Martin G Pomper; Shawn E Lupold; Catherine A Foss
Journal:  Prostate       Date:  2015-10-26       Impact factor: 4.104

8.  Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.

Authors:  Steven P Rowe; Katarzyna J Macura; Anthony Ciarallo; Esther Mena; Amanda Blackford; Rosa Nadal; Emmanuel S Antonarakis; Mario A Eisenberger; Michael A Carducci; Ashley E Ross; Philip W Kantoff; Daniel P Holt; Robert F Dannals; Ronnie C Mease; Martin G Pomper; Steve Y Cho
Journal:  J Nucl Med       Date:  2015-10-22       Impact factor: 10.057

9.  Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen.

Authors:  Ying Chen; Mrudula Pullambhatla; Sangeeta R Banerjee; Youngjoo Byun; Marigo Stathis; Camilo Rojas; Barbara S Slusher; Ronnie C Mease; Martin G Pomper
Journal:  Bioconjug Chem       Date:  2012-12-04       Impact factor: 4.774

10.  Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.

Authors:  Steve Y Cho; Kenneth L Gage; Ronnie C Mease; Srinivasan Senthamizhchelvan; Daniel P Holt; Akimosa Jeffrey-Kwanisai; Christopher J Endres; Robert F Dannals; George Sgouros; Martin Lodge; Mario A Eisenberger; Ronald Rodriguez; Michael A Carducci; Camilo Rojas; Barbara S Slusher; Alan P Kozikowski; Martin G Pomper
Journal:  J Nucl Med       Date:  2012-12       Impact factor: 10.057
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.